|  | Luminal A | χ2 p-value | Univariate analysis |  | Multivariate analysis |  |
---|---|---|---|---|---|---|---|
 |  |  |  | OR (CI 95%)a | p-value | OR (CI 95%)a | p-value |
No. of patients | Â | 45 | Â | Â | Â | Â | Â |
Tumour size | Median (mm) Range (mm) | 18 6–100 |  |  |  |  |  |
 ≥ 2 cm |  | 19/45 | 0.024 | 0.438 (0.213–0.902) | 0.025 | 0.411 (0.151–1.118) | 0.082 |
T2 intensity | Hypointensity Isointensity Hyperintensity | 20/45 12/45 13/45 | 0.941 | 0.945 (0.464–1.927) 1.154 (0.513–2.595) 0.939 (0.431–2.043) | 0.877 0.729 0.873 |  |  |
Mass enhancement |  | 35/45 | 0.525 | 0.753 (0.313–1.810) | 0.526 |  |  |
Rim enhancement |  | 3/35 | < 0.001 | 0.101 (0.029–0.358) | < 0.001 | 0.163 (0.040–0.657) | 0.011 |
Intralesional necrosis |  | 10/45 | 0.001 | 0.252 (0.112–0.566) | 0.001 | 0.711 (0.228–2.220) | 0.557 |
Perilesional oedema |  | 12/45 | < 0.001 | 0.199 (0.091–0.436) | < 0.001 | 0.419 (0.149–1.175) | 0.098 |
Abnormal lymph nodes |  | 10/45 | 0.01 | 0.352 (0.157–0.791) | 0.012 | 0.600 (0.212–1.693) | 0.334 |
Intensity-to-time curve | Type I Type II Type III | 4/45 11/45 30/45 | 0.977 | 1.073 (0.306–3.769) 0.919 (0.405–2.083) 1.048 (0.495–2.216) | 0.912 0.839 0.903 |  |  |
ADC value | Very low Low Intermediate | 20/40 19/40 1/40 | 0.182 | 0.491 (0.228–1.058) 1.944 (0.899–4.200) 2.154 (0.131–35.34) | 0.069 0.091 0.591 |  |  |
Extent of disease | Unifocal Multifocal Multicentric | 19/45 10/45 16/45 | 0.148 | 0.828 (0.405–1.692) 0.599 (0.263–1.364) 2.097 (0.957–4.593) | 0.605 0.222 0.064 |  |  |